Comparison 3. S‐adenosyl methionine versus SSRI antidepressant agent as monotherapy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Efficacy. Change in mean scores from baseline to end of treatment on depression rating scale (negative value = improvement)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
1.1 vs. escitalopram	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2 Acceptability. Participants dropping out of treatment during study period for any reason	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 vs. escitalopram	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Acceptability. Participants dropping out of treatment during study period because of adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 vs. escitalopram	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Efficacy. Response to treatment, defined as a ≥ 50% reduction in depression score from baseline to end of treatment	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 vs. escitalopram	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
5 Efficacy. Remission, defined as a depression rating scale score within normal range at end of study	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
5.1 vs. escitalopram	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6 Acceptability. Participants dropping out for any reasons other than adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
6.1 vs. escitalopram	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]